Clinical Trials in Italy

• A phase II study on adjuvant vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: neu… Recruiting
  2023-510251-31-00 Phase II neuroendocrine tumors Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
• Randomized Controlled Trial comparing two groups of Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity: the first one r… Recruiting
  2024-517858-10-00 Phase II high-risk soft tissue sarcoma of the extremity (undifferenti… Fondazione IRCCS Istituto Nazionale Dei Tumori; Sarcoma Alliance for Research th…
• SIOP RANDOMET 2017 Recruiting
  2023-508926-91-00 Phase III Stage IV childhood renal tumour with pulmonary +/- non-pulmo… GPOH gGmbH
• A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting
  2023-509699-41-00 Phase I/II Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumo… Incyte Biosciences International S.a.r.l.
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c… Recruiting
  2023-510516-39-00 Phase II Acute B-cell Lymphoblastic Leukemia with minimal residual po… Fondazione Gimema Franco Mandelli Onlus
• Long-term efficacy, safety and tolerability of LNP023 in C3G or IC-MPGN Recruiting
  2023-509343-27-00 Phase III/IV C3 Glomerulopathy or idiopathic immune-complex membranoproli… Novartis Pharma AG
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva… Recruiting
  2024-513372-18-00 Phase II Pre- and post-menopausal women with HR+/HER2- LABC or MBC wh… Consorzio Oncotech
• Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia Recruiting
  2022-502499-22-00 Phase II Beta (β) Thalassemia Celgene Corp.
• A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatoce… Recruiting
  2023-507689-26-00 Phase III Histologically or cytologically confirmed Locoregional Hepat… Astrazeneca AB
• Phase 3, Open-label Apremilast Pediatric Long-term Extension Study in Children with Oral Ulcers Associated With Behçet’s Disease or Juvenile… Recruiting
  2023-503433-21-00 Phase III Behçet’s disease is a chronic, relapsing, multisystem inflam… Amgen Inc.
• Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and Ad… Recruiting
  2024-512321-84-00 Phase III Patients after HSCT suffering from new or reactivated CMV or… Medical Center - University Of Freiburg
• Cabozantinib plus Durvalumab in patients with advanced and chemotherapy-treated bladder carcinoma, of urothelial and non-urothelial histolog… Recruiting
  2023-509821-29-00 Phase II bladder carcinoma of urothelial and non-urothelial histology Fondazione IRCCS Istituto Nazionale Dei Tumori
• Clinical utility of a next generation sequencing-based “oncochip” for therapeutic decision in metastatic breast cancer. Study SHARP Recruiting
  2024-513934-40-00 Phase II Metastatic breast cancer Istituto Europeo Di Oncologia S.r.l.
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting
  2023-506131-15-00 Phase III Juvenile Idiopathic Arthritis Eli Lilly & Co.
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 Phase III Lymphoblastic lymphoma Universitaetsklinikum Muenster AöR
• Bacille Calmette-Guérin (BCG) vaccine in Radiologically Isolated Syndrome (RIS) Recruiting
  2024-518901-16-00 Phase II RIS (Radiologically Isolated Syndrome) Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
• CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting
  2024-518987-11-00 Phase II ADCC IRCCS Istituto Nazionale Tumori Fondazione Pascale
• A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting
  2023-508302-24-00 Phase II Locally Advanced/Metastatic Urothelial Cancer Gilead Sciences Inc.
• A double blind, double dummy, multicenter, randomized, placebo- and active-controlled clinical trial to evaluate effectiveness of Tricortin … Recruiting
  2024-512292-12-00 Phase IV Low Back Pain Fidia Farmaceutici S.p.A.
• A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injec… Recruiting
  2024-513022-29-00 Phase III Major Depression Disorders Mylan Inc.
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 Phase II/III Defined by parent protocol. The study will enroll all adult … Celgene Corp.
• A randomized, double-blind, placebo-controlled, multicenter clinical trial to assess safety and effectiveness of Liposom in enhance and spee… Recruiting
  2024-512293-10-00 Phase IV Major Depressive Disorder in elderly patients Fidia Farmaceutici S.p.A.
• A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer Recruiting
  2024-515686-34-00 Phase II BRCA-related metastatic breast cancer Azienda Ospedaliero Universitaria Di Modena
• A Repeated Dose-finding Study of Sarilumab in Children and Adolescents with Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting
  2024-512701-11-00 Phase II Systemic Juvenile Idiopathic Arthritis (sJIA) Sanofi-Aventis Recherche & Developpement

Showing 1,777–1,800 of 3,692 trials